P-gp inhibitor 30

P-gp inhibitor 30 (compound A38) (0.1 μM) reverses ADM resistance in MDA-MB-231/ADM cells, potently reducing the IC₅₀ of ADM from 785.46 μM to 2.05 μM^[1].
P-gp inhibitor 30 (0.125-4 μM) significantly inhibits P-gp ATPase activity at different concentrations in a concentration-dependent manner^[1].
P-gp inhibitor 30 interacts with P-gp to inhibit its function without downregulating its expression, and stabilizes the protein, thereby reducing its degradation in MCF7/ADM cells upon increasing temperature^[1].
P-gp inhibitor 30 (6 h) significantly increases Rh123 intensity in MCF7/ADM cells and increases the accumulation of ADM and inhibits the efflux of Rh123 in MDA-MB-231/ADM cells^[1].
P-gp inhibitor 30 (0.1-1 μM, 24 h-15 days) promotes apoptosis, inhibits cell proliferation, and suppresses the migration and invasion of breast cancer drug-resistant cells (MCF7/ADM and MDA-MB-231/ADM cells), when combined with ADM, demonstrating that it sensitizes these cells to ADM^[1].
P-gp inhibitor 30 (0.1 μM) leads to the accumulation of autophagosomes and significantly increases the expression of autophagy-related proteins in MCF7/ADM and MDA-MB-231/ADM cells when combined with ADM, thereby inducing cell death^[1].
P-gp inhibitor 30 (1-10 days) significantly reduces the tumor volume of both MCF7/ADM and MDA-MB-231/ADM cells when combined with ADM in a 3D tumor spheroid model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.